Merck, Inc.
🇵🇭Philippines
MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011).
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- Drug: PlaceboDrug: MK-0941
- First Posted Date
- 2008-09-17
- Last Posted Date
- 2015-03-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT00754130
Ezetrol Post-Marketing Study
- First Posted Date
- 2008-09-17
- Last Posted Date
- 2008-09-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00753883
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Phase 1
Completed
- Conditions
- Non-Small Cell Lung CarcinomaUpper GI Tract CarcinomaColon CarcinomaMelanomaProstate CancerRenal Cell CarcinomaBreast CancerBladder Carcinoma
- Interventions
- Biological: V934-EPBiological: V935
- First Posted Date
- 2008-09-16
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 37
- Registration Number
- NCT00753415
Treatment With Infliximab in a Medical Setting (Study P05587)
Phase 4
Terminated
- Conditions
- Crohn's Disease
- Interventions
- Biological: Infliximab 5 mg/kgBiological: Infliximab 5 mg/kg every 6 weeksBiological: Infliximab 7 mg/kg every 8 weeks
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT00752622
Plasma Levels of MK0633 in Children Ages 6-12 (0633-023)
Phase 1
Completed
- Conditions
- Asthma
- First Posted Date
- 2008-09-12
- Last Posted Date
- 2015-06-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 22
- Registration Number
- NCT00751413
Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)
Phase 3
Terminated
- Conditions
- Sleep Disorders, IntrinsicSleep Initiation and Maintenance DisordersDyssomniasSleep DisordersMental Disorders
- Interventions
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 184
- Registration Number
- NCT00750919
Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)
Phase 3
Completed
- Conditions
- Neuromuscular Blockade
- Interventions
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2015-06-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 161
- Registration Number
- NCT00751179
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)
- First Posted Date
- 2008-09-10
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00750178
Remicade Safety Line (Study P03236)(COMPLETED)
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Biological: Infliximab
- First Posted Date
- 2008-09-09
- Last Posted Date
- 2015-09-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 576
- Registration Number
- NCT00748826
Photographic Library of Moderate to Severe Psoriasis Subjects Treated With Infliximab (Study P05047)
Completed
- Conditions
- Psoriasis
- Interventions
- Biological: Infliximab
- First Posted Date
- 2008-09-09
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 133
- Registration Number
- NCT00749398
© Copyright 2025. All Rights Reserved by MedPath